<DOC>
	<DOCNO>NCT02724345</DOCNO>
	<brief_summary>To evaluate analyse clinical effect application value postoperative adjuvant TACE treatment patient different expression level CK18 use randomize control study provide evidence necessity postoperative adjuvant TACE .</brief_summary>
	<brief_title>Postoperative Adjuvant TACE Treatment CK18 Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Via clinical diagnosis confirm primary liver cancer 2 . Pathological evidence HCC 3 . Estimate tumor gain treatment cure operation 4 . No evidence extrahepatic metestasis 5. liver function ：ChildPugh A/B 1. reject attend； 2. impossible come hospital physical examination regularly . 3. cancer epitome、seed focus、lymph node distant metastasis 4 . Blood clot function hindrance ; 5 , Patients disease may affect treatment mention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cell keratin 18</keyword>
</DOC>